United States Biotechnology & Medical Research

PhaseBio Pharmaceuticals Inc (PHAS)

Track

Ticker: PHAS Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for PhaseBio Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 25 Oct 2022
Value US$4,978,942.44 | Price 277.64 | Shares 75,544 (+47.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-10-26 2022-10-25 S Sale
2.5
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
75,544 +47.0%
277.64
US$4,978,942 		75,544 +47.0% 277.64 US$4,978,942
2022-05-24 2022-05-23 PlS Planned sale
1.8
Burkhardt Glen

SVP of Human Resources

Officer
60,749 -19.8%
462.01
US$2,876,297 		60,749 -19.8% 462.01 US$2,876,297
2021-11-23 2021-11-19 PlS Planned sale
1.8
Burkhardt Glen

VP, Human Resources

Officer
92,380 +20.7%
207.32
US$4,234,913 		92,380 +20.7% 207.32 US$4,234,913
2021-05-24 2021-05-20 S Sale
1.8
Burkhardt Glen

VP, Human Resources

Officer
3,811 -100.0%
3.29
US$12,538 		3,811 -100.0% 3.29 US$12,538
2020-12-04 2020-12-03 B Purchase
0.8
HARRIGAN EDMUND
Non-Executive Director
6,000 +inf%
4.12
US$24,720 		6,000 +inf% 4.12 US$24,720
2020-11-24 2020-11-24 B Purchase
3.7
Thorp Clay
Non-Executive Director
2,000 +9.5%
3.50
US$7,000 		2,000 +9.5% 3.50 US$7,000
2020-11-24 2020-11-23 B Purchase
3.7
Thorp Clay
Non-Executive Director
3,000 +16.7%
3.67
US$11,010 		3,000 +16.7% 3.67 US$11,010
2020-11-23 2020-11-23 S Sale
1.8
Burkhardt Glen

VP, Human Resources

Officer
3,497 -100.0%
3.45
US$12,065 		3,497 -100.0% 3.45 US$12,065
2019-07-03 2019-07-01 PlS Planned sale
3.7
Thorp Clay
Large shareholder
459 -0.1%
14.00
US$6,426 		459 -0.1% 14.00 US$6,426
2019-07-03 2019-07-01 PlS Planned sale
3.7
Thorp Clay
Large shareholder
255 -0.5%
14.00
US$3,570 		255 -0.5% 14.00 US$3,570
2019-07-03 2019-07-01 PlS Planned sale
3.7
Thorp Clay
Large shareholder
180 -0.1%
14.00
US$2,520 		180 -0.1% 14.00 US$2,520
2019-07-03 2019-07-01 PlS Planned sale
3.7
Thorp Clay
Large shareholder
2,014 -0.1%
14.00
US$28,196 		2,014 -0.1% 14.00 US$28,196
2019-06-20 2019-06-18 PlS Planned sale
3.7
Thorp Clay
Large shareholder
63 -0.0%
14.00
US$882 		63 -0.0% 14.00 US$882
2019-06-20 2019-06-18 PlS Planned sale
3.7
Thorp Clay
Large shareholder
35 -0.1%
14.00
US$490 		35 -0.1% 14.00 US$490
2019-06-20 2019-06-18 PlS Planned sale
3.7
Thorp Clay
Large shareholder
25 -0.0%
14.00
US$350 		25 -0.0% 14.00 US$350
2019-06-20 2019-06-18 PlS Planned sale
3.7
Thorp Clay
Large shareholder
277 -0.0%
14.00
US$3,878 		277 -0.0% 14.00 US$3,878
2018-12-17 2018-12-17 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
1,000 +inf%
4.46
US$4,460 		1,000 +inf% 4.46 US$4,460
2018-12-17 2018-12-13 B Purchase Ballance David James

VP, Research and Sci. Affairs

Officer
1,000 +15.2%
3.94
US$3,940 		1,000 +15.2% 3.94 US$3,940
2018-12-17 2018-12-13 B Purchase
1.9
Mow Jonathan P

Chief Executive Officer

Executive Director
1,000 +2.0%
3.69
US$3,690 		1,000 +2.0% 3.69 US$3,690
2018-12-11 2018-12-11 B Purchase York Michael

VP, Corporate Development

Officer
1,500 +inf%
3.88
US$5,820 		1,500 +inf% 3.88 US$5,820
2018-12-11 2018-12-10 B Purchase
1.9
Mow Jonathan P

Chief Executive Officer

Executive Director
800 +1.6%
3.85
US$3,080 		800 +1.6% 3.85 US$3,080
2018-12-11 2018-12-07 B Purchase
1.6
Sharp John P

CFO and Secretary

Officer
5,000 +inf%
3.84
US$19,200 		5,000 +inf% 3.84 US$19,200
2018-12-11 2018-12-07 B Purchase
1.9
Mow Jonathan P

Chief Executive Officer

Executive Director
2,200 +4.5%
3.88
US$8,536 		2,200 +4.5% 3.88 US$8,536
2018-12-06 2018-12-04 B Purchase
3.7
Thorp Clay
Non-Executive Director Large shareholder
4,000 +33.9%
3.13
US$12,520 		4,000 +33.9% 3.13 US$12,520
2018-10-24 2018-10-22 B Purchase
3.7
Thorp Clay
Non-Executive Director Large shareholder
150,000 +56.3%
5.00
US$750,000 		150,000 +56.3% 5.00 US$750,000
2018-10-24 2018-10-22 B Purchase
3.7
Thorp Clay
Non-Executive Director Large shareholder
12,487 +8.3%
5.00
US$62,435 		12,487 +8.3% 5.00 US$62,435
2018-10-24 2018-10-22 B Purchase
3.7
Thorp Clay
Non-Executive Director Large shareholder
137,513 +8.2%
5.00
US$687,565 		137,513 +8.2% 5.00 US$687,565
2018-10-24 2018-10-22 B Purchase ASTRAZENECA PLC Large shareholder
600,000 +25.0%
5.00
US$3,000,000 		600,000 +25.0% 5.00 US$3,000,000
2018-10-24 2018-10-22 B Purchase NEW ENTERPRISE ASSOCIATES 13 LP Large shareholder
1,800,000 +37.2%
5.00
US$9,000,000 		1,800,000 +37.2% 5.00 US$9,000,000
2018-10-24 2018-10-22 B Purchase TUFTS LINDA Non-Executive Director
6,041 +2.2%
5.00
US$30,205 		6,041 +2.2% 5.00 US$30,205
2018-10-24 2018-10-22 B Purchase TUFTS LINDA Non-Executive Director
1,277 +2.2%
5.00
US$6,385 		1,277 +2.2% 5.00 US$6,385
2018-10-24 2018-10-22 B Purchase TUFTS LINDA Non-Executive Director
12,682 +2.2%
5.00
US$63,410 		12,682 +2.2% 5.00 US$63,410
2018-10-24 2018-10-22 B Purchase Hatteras Venture Advisors III, LLC Large shareholder
150,000 +56.3%
5.00
US$750,000 		150,000 +56.3% 5.00 US$750,000
2018-10-24 2018-10-22 B Purchase Hatteras Venture Advisors III, LLC Large shareholder
12,487 +8.3%
5.00
US$62,435 		12,487 +8.3% 5.00 US$62,435
2018-10-24 2018-10-22 B Purchase Hatteras Venture Advisors III, LLC Large shareholder
137,513 +8.2%
5.00
US$687,565 		137,513 +8.2% 5.00 US$687,565
Explore more

More insider trading research around PhaseBio Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America